Published - September 12th, 2023 @ 8:40 AM (GMT+2)
‍

A Deep Dive into Novo Nordisk's New Options and Stock Momentum

‍

Novo Nordisk A/S (NYSE:NVO), a healthcare giant specializing in diabetes and obesity care, has recently been the subject of much investor attention. The company's stock has been on a bullish run, and new options have been introduced that could offer lucrative opportunities for both buyers and sellers. Here's what you need to know.

‍

January 2026 Options Unveiled

‍

Investors have a new playground with the introduction of options expiring in January 2026. These options offer a time value of 858 days until expiration, providing a unique opportunity for investors to achieve higher premiums. Specifically, the put contract at the $195.00 strike price has a current bid of $25.80, offering an attractive alternative to buying shares at the current price of $199.54.

‍

Analyzing the YieldBoost Formula

‍

The YieldBoost formula at Stock Options Channel indicates that the odds of the $195.00 strike put contract expiring worthless are 99%. If that happens, the premium would represent a 13.23% return on the cash commitment, or an annualized return of 5.63%. On the flip side, the call contract at the $200.00 strike price has a current bid of $42.90, with a 99% chance of expiring worthless. If it does, the premium would boost the investor's return by 21.72%, or 9.24% annualized.

‍

Stock Performance and Future Projections

‍

Novo Nordisk's stock has been performing exceptionally well. As of September 11, 2023, the stock closed at $199.54, marking an 11.20% increase since last month and an astounding 82.51% increase since last year. The company's market cap stands at 340.89B USD, with an average volume of 1.96M. The stock is expected to see further upside, especially in the short term.

‍

Conclusion

‍

Novo Nordisk offers a compelling investment opportunity, especially with the introduction of new options expiring in January 2026. The stock's robust performance, coupled with favorable option contracts, makes it a strong candidate for portfolio inclusion. Investors looking for both short-term gains and long-term stability should consider Novo Nordisk.

‍
‍
The information on mexem.com is for general informational purposes only. It should not be regarded as investment advice. Investing in stocks involves risk. A stock's past performance is not a reliable indicator of its future performance. Always consult a financial advisor or trusted sources before making any investment decisions.
‍
‍